The next generation biopharmaceuticals
Affibody Presents at Bio€quity Europe
Solna, Sweden, May 11, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that it is presenting the company at Bio€quity Europe, an investor and partnering event.
David Bejker, CEO, will present an overview of Affibody’s technology and the multiple value driving clinical, business development, and commercial opportunities available based on this proprietary platform Wednesday May 16 at 11:40am (CEST) at Het Pand, Onderbergen 1, 9000 Ghent, Belgium.
“We are excited to present and discuss our science driven experimental medicine model and the valuable milestones we expect to meet in the next twelve to eighteen months. Specifically, the key milestones related to the rapid expansion of our clinical portfolio”, said David Bejker, CEO of Affibody. “We will also highlight that we continue to systematically build our company based on the development of multiple new products from our innovative proprietary platform. Bio€quity Europe is an ideal area for us to share this due to the high quality of participants.”
Affibody is a clinical stage Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has four clinical or late stage preclinical proprietary programs. The first three are therapeutic programs that targets psoriasis, B-cell driven autoimmune diseases, and liver diseases respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.
Affibody has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report January to March 2020 (May 15, 2020)
- Interim Report January to June 2020 (August 21, 2020)
- Interim Report January to September 2020 (November 13, 2020)
- Year End Report 2020 (February 2021)